Human NAD(P)H:Quinone oxidoreductase type i (hNQO1) activation of quinone propionic acid trigger groups

Biochemistry

Volumn 51, Issue 40, 2012, Pages 8014-8026

  Mendoza, Maria F ^a   Hollabaugh, Nicole M ^a   Hettiarachchi, Suraj U ^a   McCarley, Robin L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCEPTOR SITES; ACTIVE DRUGS; ACTIVE SITE; CATALYTIC CONSTANTS; CATALYTIC EFFICIENCIES; DRUG DELIVERY APPLICATIONS; ENVIRONMENTAL STIMULI; GOOD CORRELATIONS; HIGH PRECISION; MAXIMUM VELOCITY; MICHAELIS CONSTANTS; MOLECULAR ASSEMBLY; MOLECULAR DOCKING SIMULATIONS; NAD(P)H; OXIDOREDUCTASES; PRODRUGS; PROPIONIC ACIDS; QUINONE RINGS; REDUCTIVE ACTIVATION; SIGNIFICANT IMPACTS; SINGLE ATOMS; TUMOR SITE;

DRUG DELIVERY; HYDRIDES; KINETIC PARAMETERS; MOLECULAR MODELING; TISSUE;

SATURATED FATTY ACIDS;

FLAVINE ADENINE NUCLEOTIDE; LIPOSOME; PRODRUG; PROPIONIC ACID DERIVATIVE; QUINONE DERIVATIVE; QUINONE PROPIONIC ACID DERIVATIVE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; KINETICS; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; SIMULATION; STRUCTURE ANALYSIS;

CATALYTIC DOMAIN; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAD(P)H DEHYDROGENASE (QUINONE); PROPIONATES; PROTEIN BINDING; QUINONES; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84867468663     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi300760u     Document Type: Article

References (99)

1. Andresen, T. L., Jensen, S. S., and Jorgensen, K. (2005) Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release Prog. Lipid Res. 44, 68-97
2. Asche, C. (2005) Antitumour quinones Mini-Rev. Med. Chem. 5, 449-467
3. de Groot, F. M. H., Damen, E. W. P., and Scheeren, H. W. (2001) Anticancer prodrugs for application in monotherapy: Targeting hypoxia, tumor-associated enzymes, and receptors Curr. Med. Chem. 8, 1093-1122
4. Jaffar, M., Abou-Zeid, N., Bai, L., Mrema, I., Robinson, I., Tanner, R., and Stratford, I. J. (2004) Quinone bioreductive prodrugs as delivery agents Curr. Drug Delivery 1, 345-350
5. Rooseboom, M., Commandeur, J. N. M., and Vermeulen, N. P. E. (2004) Enzyme-catalyzed activation of anticancer prodrugs Pharmacol. Rev. 56, 53-102
6. Chen, Y. and Hu, L. Q. (2009) Design of anticancer prodrugs for reductive activation Med. Res. Rev. 29, 29-64
7. Davis, S. C. and Szoka, F. C. (1998) Cholesterol phosphate derivatives: Synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome Bioconjugate Chem. 9, 783-792
8. Davidsen, J., Vermehren, C., Frokjaer, S., Mouritsen, O. G., and Jorgensen, K. (2001) Drug delivery by phospholipase A(2) degradable liposomes Int. J. Pharm. 214, 67-69
9. Jorgensen, K., Davidsen, J., and Mouritsen, O. G. (2002) Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug delivery FEBS Lett. 531, 23-27
10. Davidsen, J., Jorgensen, K., Andresen, T. L., and Mouritsen, O. G. (2003) Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue Biochim. Biophys. Acta 1609, 95-101
11. Meers, P. (2001) Enzyme-activated targeting of liposomes Adv. Drug Delivery Rev. 53, 265-272
12. Sarkar, N., Banerjee, J., Hanson, A. J., Elegbede, A. I., Rosendahl, T., Krueger, A. B., Banerjee, A. L., Tobwala, S., Wang, R. Y., Lu, X. N., Mallik, S., and Srivastava, D. K. (2008) Matrix metalloproteinase-assisted triggered release of liposomal contents Bioconjugate Chem. 19, 57-64
13. Banerjee, J., Hanson, A. J., Gadam, B., Elegbede, A. I., Tobwala, S., Ganguly, B., Wagh, A. V., Muhonen, W. W., Law, B., Shabb, J. B., Srivastava, D. K., and Mallik, S. (2009) Release of liposomal contents by cell-secreted matrix metalloproteinase-9 Bioconjugate Chem. 20, 1332-1339
14. Reigan, P., Colucci, M. A., Siegel, D., Chilloux, A., Moody, C. J., and Ross, D. (2007) Development of indolequinone mechanism-based inhibitors of NAD(P)H: quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells Biochemistry 46, 5941-5950
15. Ernster, L. (1987) DT-Diaphorase-a historical review Chem. Scripta 27A, 1-13
16. Ernster, L. and Navazio, F. (1958) Soluble diaphorase in animal tissues Acta Chem. Scand. 12, 595-595
17. Siegel, D., Reigan, P., and Ross, D. (2008) One- and two-electron- mediated reduction of quinones: enzymology and toxicological implications Biotechnology: Pharm. Aspects 9, 169-197
18. Iyanagi, T. and Yamazaki, I. (1970) One-electron-transfer reactions in biochemical systems 0.5. Difference in mechanism of quinone reduction by NADH dehydrogenase and NAD(P)H dehydrogenase (DT-diaphorase) Biochim. Biophys. Acta 216, 282-294
19. Winski, S. L., Koutalos, Y., Bentley, D. L., and Ross, D. (2002) Subcellular localization of NAD(P)H: quinone oxidoreductase 1 in human cancer cells Cancer Res. 62, 1420-1424
20. Villalba, J. M., Navarro, F., Arroyo, A., Martin, S. F., Bello, R. I., de Cabo, R., Burgess, J. R., and Navas, P. (1999) Protective role of ubiquinone in vitamin E and selenium-deficient plasma membranes Biofactors 9, 163-170
21. Ernster, L. (1967) DT Diaphorase Methods Enzymol. 10, 309-317
22. Nakamura, M. and Hayashi, T. (1994) One-electron and 2-electron reduction of quinones by rat-liver subcellular-fractions J. Biochem.-Tokyo 115, 1141-1147
23. Siegel, D., McGuinness, S. M., Winski, S. L., and Ross, D. (1999) Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H: quinone oxidoreductase 1 Pharmacogenetics 9, 113-121
24. Sreerama, L., Hedge, M. W., and Sladek, N. E. (1995) Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli Clin. Cancer Res. 1, 1153-1163
25. Reicks, M. M. and Appelt, L. C. (1999) Soy induces phase II enzymes but does not inhibit dimethylbenz[a]anthracene-induced carcinogenesis in female rats J. Nutr. 129, 1820-1826
26. Cresteil, T. and Jaiswal, A. K. (1991) High-levels of expression of the NAD(P)H-quinone oxidoreductase (NQO1) gene in tumor-cells compared to normal-cells of the same origin Biochem. Pharmacol. 42, 1021-1027
27. Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R., and Lewis, A. D. (1996) Reductase enzyme expression across the national cancer institute tumor cell line panel: Correlation with sensitivity to mitomycin C and E09 J. Natl. Cancer Inst. 88, 259-269
28. Siegel, D., Franklin, W. A., and Ross, D. (1998) Immunohistochemical detection of NAD(P)H: Quinone oxidoreductase in human lung and lung tumors Clin. Cancer Res. 4, 2065-2070
29. Siegel, D. and Ross, D. (2000) Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues Free Radical Biol. Med. 29, 246-253
30. Jamieson, D., Wilson, K., Pridgeon, S., Margetts, J. P., Edmondson, R. J., Leung, H. Y., Knox, R., and Boddy, A. V. (2007) NAD(P)H: quinone oxidoreductase1 and NRH: quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH: quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism Clin. Cancer Res. 13, 1584-1590
31. Volpato, M., Abou-Zeid, N., Tanner, R. W., Glassbrook, L. T., Taylor, J., Stratford, I., Loadman, P. M., Jaffar, M., and Phillips, R. M. (2007) Chemical synthesis and biological evaluation of a NAD(P)H: quinone oxidoreductase-1- targeted tripartite quinone drug delivery system Mol. Cancer Ther. 6, 3122-3130
32. Ong, W., Yang, Y. M., Cruciano, A. C., and McCarley, R. L. (2008) Redox-triggered contents release from liposomes J. Am. Chem. Soc. 130, 14739-14744
33. Faig, M., Bianchet, M. A., Talalay, P., Chen, S., Winski, S., Ross, D., and Amzel, L. M. (2000) Structures of recombinant human and mouse NAD(P)H: quinone oxidoreductases: Species comparison and structural changes with substrate binding and release Proc. Natl. Acad. Sci. U. S. A. 97, 3177-3182
34. Li, R., Bianchet, M. A., Talalay, P., and Amzel, L. M. (1995) The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two-electron reduction Proc. Natl. Acad. Sci. U. S. A. 92, 8846-8850
35. Faig, M., Bianchet, M. A., Winski, S., Hargreaves, R., Moody, C. J., Hudnott, A. R., Ross, D., and Amzel, L. M. (2001) Structure-based development of anticancer drugs: Complexes of NAD(P)H: quinone oxidoreductase 1 with chemotherapeutic quinones Structure 9, 659-667
36. Winski, S. L., Faig, M., Bianchet, M. A., Siegel, D., Swann, E., Fung, K., Duncan, M. W., Moody, C. J., Amzel, L. M., and Ross, D. (2001) Characterization of a mechanism-based inhibitor of NAD(P)H: Quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches Biochemistry 40, 15135-15142
37. Asher, G., Dym, O., Tsvetkov, P., Adler, J., and Shaul, Y. (2006) The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol Biochemistry 45, 6372-6378
38. Nolan, K. A., Doncaster, J. R., Dunstan, M. S., Scott, K. A., Frenkel, A. D., Siegel, D., Ross, D., Barnes, J., Levy, C., Leys, D., Whitehead, R. C., Stratford, I. J., and Bryce, R. A. (2009) Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1) J. Med. Chem. 52, 7142-7156
39. Danson, S., Ward, T. H., Butler, J., and Ranson, M. (2004) DT-diaphorase: a target for new anticancer drugs Cancer Treatment Rev. 30, 437-449
40. Colucci, M. A., Moody, C. J., and Couch, G. D. (2008) Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential Org. Biomol. Chem. 6, 637-656
41. Weerapreeyakul, N., Anorach, R., Khuansawad, T., Yenjai, C., and Isaka, M. (2007) Synthesis of bioreductive esters from fungal compounds Chem. Pharm. Bull. 55, 930-935
42. Silvers, W. C., Payne, A. S., and McCarley, R. L. (2011) Shedding light by cancer redox-human NAD(P)H:quinone oxidoreductase 1 activation of a cloaked fluorescent dye Chem. Commun. 10.1039/c1cc14578a
43. Huang, S. T. and Lin, Y. L. (2006) New latent fluorophore for DT diaphorase Org. Lett. 8, 265-268
44. Volpato, M., Abou-Zeid, N., Tanner, R. W., Glassbrook, L. T., Taylor, J., Stratford, I., Loadman, P., Jaffar, M., and Phillips, R. M. (2007) Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1- targeted tripartite quinone drug delivery system Mol. Cancer Ther. 6, 3122-3130
45. Moody, C. J., Maskell, L., Blanche, E. A., Colucci, M. A., and Whatmore, J. L. (2007) Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles Bioorg. Med. Chem. Lett. 17, 1575-1578
46. Ingold, C. K., Sako, S., and Thorpe, J. F. (1922) Influence of substituents on the formation and stability of heterocyclic compounds. I. Hydantoins J. Chem. Soc., Trans. 121, 1177-1198
47. Milstien, S. and Cohen, L. A. (1972) Stereopopulation control 0.1. rate enhancement in lactonizations of ortho-hydroxyhydrocinnamic acids J. Am. Chem. Soc. 94, 9158-9165
48. Jung, M. E. and Piizzi, G. (2005) gem-Disubstituent effect: theoretical basis and synthetic applications Chem. Rev. 105, 1735-1766
49. Beall, H. D., Murphy, A. M., Siegel, D., Hargreaves, R. H. J., Butler, J., and Ross, D. (1995) Nicotinamide adenine-dinucleotide (phosphate):quinone oxidoreductase (DT-Diaphorase) as a target for bioreductive antitumor quinones-quinone cytotoxicity and selectivity in human lung and breast-cancer cell-lines Mol. Pharmacol. 48, 499-504
50. Phillips, R. M. (1996) Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase Biochem. Pharmacol. 52, 1711-1718
51. Beall, H. D., Winski, S., Swann, E., Hudnott, A. R., Cotterill, A. S., O'Sullivan, N., Green, S. J., Bien, R., Siegel, D., Ross, D., and Moody, C. J. (1998) Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H: quinone oxidoreductase, and in vitro cytotoxicity J. Med. Chem. 41, 4755-4766
52. Swann, E., Barraja, P., Oberlander, A. M., Gardipee, W. T., Hudnott, A. R., Beall, H. D., and Moody, C. J. (2001) Indolequinone antitumor agents: Correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H: quinone oxidoreductase. Part 2 J. Med. Chem. 44, 3311-3319
53. Fourie, J., Oleschuk, C. J., Guziec, F., Guziec, L., Fiterman, D. J., Monterrosa, C., and Begleiter, A. (2002) The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase Cancer Chemother. Pharmacol. 49, 101-110
54. Fryatt, T., Pettersson, H. I., Gardipee, W. T., Bray, K. C., Green, S. J., Slawin, A. M. Z., Beall, H. D., and Moody, C. J. (2004) Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H: quinone oxidoreductase (NQO1) Bioorg. Med. Chem. 12, 1667-1687
55. Newsome, J. J., Swann, E., Hassani, M., Bray, K. C., Slawin, A. M. Z., Beall, H. D., and Moody, C. J. (2007) Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H: quinone oxidoreductase Org. Biomol. Chem. 5, 1629-1640
56. Begleiter, A., El-Gabalawy, N., Lange, L., Leith, M. K., Guziec, L. J., and Guziec, F. S., Jr (2009) A model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) targeted individualized cancer chemotherapy Drug Target Insights 4, 1-8
57. Fagan, V., Bonham, S., Carty, M. P., Saenz-Méndez, P., Eriksson, L. A., and Aldabbagh, F. (2012) COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates Bioorg. Med. Chem. 20, 3223-3232
58. Skelly, J. V., Sanderson, M. R., Suter, D. A., Baumann, U., Read, M. A., Gregory, D. S. J., Bennett, M., Hobbs, S. M., and Neidle, S. (1999) Crystal structure of human DT-diaphorase: A model for interaction with the cytotoxic prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) J. Med. Chem. 42, 4325-4330
59. Suleman, A. and Skibo, E. B. (2002) A comprehensive study of the active site residues of DT-diaphorase: Rational design of benzimidazolediones as DT-diaphorase substrates J. Med. Chem. 45, 1211-1220
60. Hassani, M., Cai, W., Koelsch, K. H., Holley, D. C., Rose, A. S., Olang, F., Lineswala, J. P., Holloway, W. G., Gerdes, J. M., Behforouz, M., and Beall, H. D. (2008) Lavendamycin antitumor agents: Structure-based design, synthesis, and NAD(P)H: Quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies J. Med. Chem. 51, 3104-3115
61. Nolan, K. A., Humphries, M. P., Barnes, J., Doncaster, J. R., Caraher, M. C., Tirelli, N., Bryce, R. A., Whitehead, R. C., and Stratford, I. J. (2010) Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2 Bioorg. Med. Chem. 18, 696-706
62. Phillips, R. M., Naylor, M. A., Jaffar, M., Doughty, S. W., Everett, S. A., Breen, A. G., Choudry, G. A., and Stratford, I. J. (1999) Bioreductive activation of a series of indolequinones by human DT-diaphorase: Structure-activity relationships J. Med. Chem. 42, 4071-4080
63. Chen, S., Knox, R., Lewis, A. D., Friedlos, F., Workman, P., Deng, P. S., Fung, M., Ebenstein, D., Wu, K., and Tsai, T. M. (1995) Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes Mol. Pharmacol. 47, 934-939
64. Chen, S., Knox, R., Wu, K., Deng, P. S. K., Zhou, D. J., Bianchet, M. A., and Amzel, L. M. (1997) Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse J. Biol. Chem. 272, 1437-1439
65. Chen, S., Wu, K., Zhang, D., Sherman, M., Knox, R., and Yang, C. S. (1999) Molecular characterization of binding of substrates and inhibitors to DT-Diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling Mol. Pharmacol. 56, 272-278
66. Anusevicius, Z., Sarlauskas, J., and Cenas, N. (2002) Two-electron reduction of quinones by rat liver NAD(P)H: quinone oxidoreductase: quantitative structure-activity relationships Arch. Biochem. Biophys. 404, 254-262
67. Čênas, N., Anusevicius, Z., Nivinskas, H., Miseviciene, L., and Sarlauskas, J. (2004) Structure-activity relationship in two-electron reduction of quinones Methods Enzymol. 382, 258-277
68. Zhou, Z. G., Fisher, D., Spidel, J., Greenfield, J., Patson, B., Fazal, A., Wigal, C., Moe, O. A., and Madura, J. D. (2003) Kinetic and docking studies of the interaction of quinones with the quinone reductase active site Biochemistry 42, 1985-1994
69. Hollabaugh Carrier, N. M. (2011) Redox-active liposome delivery agents with highly controllable stimuli-responsive behavior, Ph.D. Dissertation, Department of Chemistry, Louisiana State University, Baton Rouge, LA.
70. Osman, A. M. and Boeren, S. (2004) Studies on the DT-diaphorase-catalysed reaction employing quinones as substrates: evidence for a covalent modification of DT-diaphorase by tetrachloro-p-benzoquinone Chem.-Biol. Interact 147, 99-108
71. Harris, D. C. (2007) Statistics, in Quantitative Chemical Analysis (Byrd, M. L., Ed.) 7 th ed., p 65, W. H. Freeman and Company, New York.
72. Cleland, W. W. (1979) Statistical analysis of enzyme kinetic data Methods Enzymol. 63, 103-138
73. Harris, D. C. (2007) Statistics, in Quantitative Chemical Analysis (Byrd, M. L., Ed.) 7 th ed., p 59, W. H. Freeman and Company, New York.
74. Bohm, H. J. (1992) The computer-program Ludi-a new method for the denovo design of enzyme-inhibitors J. Comput. Aid. Mol. Des. 6, 61-78
75. Bohm, H. J. (1994) The development of a simple empirical scoring function to estimate the binding constant for a protein ligand complex of known 3-dimensional structure J. Comput. Aid. Mol. Des. 8, 243-256
76. Rarey, M., Wefing, S., and Lengauer, T. (1996) Placement of medium-sized molecular fragments into active sites of proteins J. Comput. Aid. Mol. Des. 10, 41-54
77. Rarey, M., Kramer, B., Lengauer, T., and Klebe, G. (1996) A fast flexible docking method using an incremental construction algorithm J. Mol. Biol. 261, 470-489
78. Rarey, M., Kramer, B., and Lengauer, T. (1997) Multiple automatic base selection: Protein-ligand docking based on incremental construction without manual intervention J. Comput. Aid. Mol. Des. 11, 369-384
79. Kramer, B., Rarey, M., and Lengauer, T. (1997) CASP2 experiences with docking flexible ligands using FLEXX Proteins 221-225
80. Kramer, B., Rarey, M., and Lengauer, T. (1999) Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking Proteins 37, 228-241
81. Rarey, M., Kramer, B., and Lengauer, T. (1999) Docking of hydrophobic ligands with interaction-based matching algorithms Bioinformatics 15, 243-250
82. Bohm, H. J. (1992) Ludi-rule-based automatic design of new substituents for enzyme-inhibitor leads J. Comput. Aid. Mol. Des. 6, 593-606
83. Ross, D. (2004) Quinone reductases multitasking in the metabolic world Drug Metab. Rev. 36, 639-654
84. Robitaille, P. M. L., Robitaille, P. A., Brown, G. G., and Brown, G. G. (1991) An analysis of the pH-dependent chemical-shift behavior of phosphorus-containing metabolites J. Magn. Reson. 92, 73-84
85. 4 Acta Crystallogr. B-Struct. B 27, 1846-1851
86. Burie, J. R., Boullais, C., Nonella, M., Mioskowski, C., Nabedryk, E., and Breton, J. (1997) Importance of the conformation of methoxy groups on the vibrational and electrochemical properties of ubiquinones J. Phys. Chem. B 101, 6607-6617
87. Lind, C., Cadenas, E., Hochstein, P., and Ernster, L. (1990) DT-Diaphorase: purification, properties, and function Methods Enzymol. 186, 287-301
88. Buffinton, G. D., Ollinger, K., Brunmark, A., and Cadenas, E. (1989) DT-diaphorase-catalyzed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates Biochem. J. 257, 561-571
89. Zhao, Y. H., Abraham, M. H., and Zissimos, A. M. (2003) Fast calculation of van der Waals volume as a sum of atomic and bond contributions and its application to drug compounds J. Org. Chem. 68, 7368-7373
90. Ryabov, A. D., Ryabova, E. S., and Reshetova, M. D. (2001) Enzymatic chemistry of ferrocenes: micellar tuning of the glucose oxidase reactivity toward solubilized electrochemically generated n -alkylferricenium cations J. Organomet. Chem. 637-639, 469-475
91. Cavelier, G. and Amzel, L. M. (2001) Mechanism of NAD(P)H: quinone reductase: Ab initio studies of reduced flavin Proteins 43, 420-432
92. Deller, S., Macheroux, P., and Sollner, S. (2008) Flavin-dependent quinone reductases Cell. Mol. Life Sci. 65, 141-160
93. Bianchet, M. A., Faig, M., and Amzel, L. M. (2004) Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO), in Quinones and quinone enzymes, Part B (Helmut, S. and Lester, P., Eds.), pp 144-174, Elsevier Academic Press.
94. Nolan, K. A., Timson, D. J., Stratford, I. J., and Bryce, R. A. (2006) In silico identification and biochemical characterization of novel inhibitors of NQO1 Bioorg. Med. Chem. Lett. 16, 6246-6254
95. Marcus, R. A. (2007) H and other transfers in enzymes and in solution: theory and computations, a unified view. 2. applications to experiment and computations J. Phys. Chem. B 111, 6643-6654
96. Roston., D. and Amnon, K. (2010) Elusive transition state of alcohol dehydrogenase unveiled Proc. Natl. Acad. Sci. U. S. A. 107, 9572-9577
97. Carlson, B. W. and Miller, L. L. (1985) Mechanism of the oxidation of NADH by quinones-energetics of one-electron and hydride routes J. Am. Chem. Soc. 107, 479-485
98. Tedeschi, G., Chen, S., and Massey, V. (1995) Active site studies of DT-diaphorase employing artificial flavins J. Biol. Chem. 270, 2512-2516
99. Tranoy-Opalinski, I., Fernandes, A., Thomas, M., Gesson, J. P., and Papot, S. (2008) Design of self-immolative linkers for tumour-activated prodrug therapy Anti-Cancer Agent. Med. Chem. 8, 618-637